SG192550A1 - Chemical compounds - Google Patents

Chemical compounds Download PDF

Info

Publication number
SG192550A1
SG192550A1 SG2013056528A SG2013056528A SG192550A1 SG 192550 A1 SG192550 A1 SG 192550A1 SG 2013056528 A SG2013056528 A SG 2013056528A SG 2013056528 A SG2013056528 A SG 2013056528A SG 192550 A1 SG192550 A1 SG 192550A1
Authority
SG
Singapore
Prior art keywords
methyl
hexahydro
carbonyl
pyrazin
dioxo
Prior art date
Application number
SG2013056528A
Other languages
English (en)
Inventor
Brian Alvin Johns
Jason Gordon Weatherhead
Toshikazu Hakogi
Yasunori Aoyama
Original Assignee
Viiv Healthcare Co
Shionogi & Co Ltd Jp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viiv Healthcare Co, Shionogi & Co Ltd Jp filed Critical Viiv Healthcare Co
Publication of SG192550A1 publication Critical patent/SG192550A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/34—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D309/36—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C07D309/40—Oxygen atoms attached in positions 3 and 4, e.g. maltol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/86—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/803—Processes of preparation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pyridine Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SG2013056528A 2008-07-25 2009-07-23 Chemical compounds SG192550A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8362108P 2008-07-25 2008-07-25

Publications (1)

Publication Number Publication Date
SG192550A1 true SG192550A1 (en) 2013-08-30

Family

ID=41570595

Family Applications (1)

Application Number Title Priority Date Filing Date
SG2013056528A SG192550A1 (en) 2008-07-25 2009-07-23 Chemical compounds

Country Status (9)

Country Link
US (7) US8580967B2 (https=)
EP (2) EP2660239B1 (https=)
JP (2) JP5586602B2 (https=)
KR (3) KR101700267B1 (https=)
CN (3) CN103951643B (https=)
ES (2) ES2562452T3 (https=)
PT (1) PT2660239T (https=)
SG (1) SG192550A1 (https=)
WO (1) WO2010011814A1 (https=)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010011814A1 (en) 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
WO2010067176A1 (en) 2008-12-11 2010-06-17 Shionogi & Co., Ltd. Maltol ether processes and intermediates
CN102245572B (zh) 2008-12-11 2015-03-25 盐野义制药株式会社 氨甲酰基吡啶酮hiv整合酶抑制剂的方法和中间体
KR101733625B1 (ko) 2008-12-11 2017-05-10 시오노기세야쿠 가부시키가이샤 카르바모일피리돈 ｈｉｖ 인테그라제 억제제 및 중간체의 합성
TWI518084B (zh) 2009-03-26 2016-01-21 鹽野義製藥股份有限公司 哌喃酮與吡啶酮衍生物之製造方法
TWI582097B (zh) * 2010-03-23 2017-05-11 Ｖｉｉｖ醫療保健公司 製備胺甲醯吡啶酮衍生物及中間體之方法
TWI577377B (zh) * 2010-09-16 2017-04-11 Ｖｉｉｖ醫療保健公司 醫藥組合物
DK2620436T3 (en) * 2010-09-24 2018-07-30 Shionogi & Co Substituted polycyclic carbamoylpyridone derivative prodrug
EA030003B1 (ru) 2012-12-21 2018-06-29 Джилид Сайэнс, Инк. Полициклическое карбамоилпиридоновое соединение и его фармацевтическое применение для лечения вич-инфекции
ES2859102T3 (es) 2013-07-12 2021-10-01 Gilead Sciences Inc Compuestos de carbamoilpiridona policíclica y su uso para el tratamiento de infecciones por VIH
NO2865735T3 (https=) 2013-07-12 2018-07-21
WO2015108945A2 (en) 2014-01-14 2015-07-23 Board Of Regents Of The University Of Nebraska Compositions and methods for the delivery of therapeutics
TWI677489B (zh) 2014-06-20 2019-11-21 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
NO2717902T3 (https=) 2014-06-20 2018-06-23
WO2016057866A1 (en) 2014-10-09 2016-04-14 Board Of Regents Of The University Of Nebraska Compositions and methods for the delivery of therapeutics
TWI695003B (zh) 2014-12-23 2020-06-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
KR20190057158A (ko) 2015-04-02 2019-05-27 길리애드 사이언시즈, 인코포레이티드 폴리시클릭-카르바모일피리돈 화합물 및 그의 제약 용도
US11117904B2 (en) * 2016-06-23 2021-09-14 Viiv Healthcare Company Compositions and methods for the delivery of therapeutics
JP2020527570A (ja) * 2017-07-18 2020-09-10 ヴィーブ ヘルスケア カンパニー 組み合わせ薬物療法
CN111386276B (zh) 2017-10-06 2023-06-23 盐野义制药株式会社 制备取代的多环吡啶酮衍生物的立体选择性方法
TWI795462B (zh) 2017-11-17 2023-03-11 日商鹽野義製藥股份有限公司 光安定性及溶出性優異的醫藥製劑
CA3126348A1 (en) 2018-01-12 2020-07-18 Board Of Regents Of The University Of Nebraska Antiviral prodrugs and formulations thereof
US11458136B2 (en) 2018-04-09 2022-10-04 Board Of Regents Of The University Of Nebraska Antiviral prodrugs and formulations thereof
EP3870174B1 (en) 2018-10-22 2023-11-01 Board of Regents of the University of Nebraska Antiviral prodrugs and nanoformulations thereof
CN120535538A (zh) 2018-11-29 2025-08-26 内布拉斯加大学董事会 抗病毒前药及其纳米制剂
MY201239A (en) 2019-03-22 2024-02-13 Gilead Sciences Inc Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use
WO2020221294A1 (zh) * 2019-04-30 2020-11-05 上海拓界生物医药科技有限公司 桥环-3,4-二氢-吡啶并[1,2-a]吡嗪-1,8-二酮化合物及其药物用途
WO2021129602A1 (zh) * 2019-12-23 2021-07-01 石家庄迪斯凯威医药科技有限公司 取代的多环化合物及其药物组合物和用途
PE20221569A1 (es) 2020-02-24 2022-10-06 Gilead Sciences Inc Compuestos tetraciclicos para el tratamiento de infecciones por vih
ES3064867T3 (en) 2020-09-30 2026-04-29 Gilead Sciences Inc Bridged tricyclic carbamoylpyridone compounds for a use in the treatment of hiv
CN114426540B (zh) * 2020-10-29 2024-04-26 上海拓界生物医药科技有限公司 吡啶并[1,2-a]吡嗪-1,8-二酮类前药衍生物、其制备方法及其应用
US11613546B2 (en) 2021-01-19 2023-03-28 Gilead Sciences, Inc. Substituted pyridotriazine compounds and uses thereof
MX2023009445A (es) * 2021-02-16 2023-08-25 Merck Sharp & Dohme Llc Compuestos de heterociclos tetraciclicos utiles como inhibidores de la integrasa del vih.
TW202446773A (zh) 2022-04-06 2024-12-01 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
CN120424092B (zh) * 2025-07-02 2025-09-12 中国人民解放军军事科学院军事医学研究院 布尼亚病毒抑制剂及其制备方法和用途

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1544199A (en) * 1922-08-21 1925-06-30 Herman Christensen Condenser
GB427857A (en) 1934-08-02 1935-05-01 Newsum Sons & Company Ltd H A new or improved system of construction for skeleton structures, particularly vehicle body frames and door frames
US4524149A (en) * 1982-03-15 1985-06-18 Sterling Drug Inc. 5-Alkanoyl-6-alkyl-2(1H)-pyridinones, their preparation and their cardiotonic use
US4769380A (en) * 1983-04-29 1988-09-06 Merrell Dow Pharmaceuticals Inc. Cardiotonic 5-benzoyl-1,2-dihydro-2-oxo-3-pyridinecarboxylates
US4603144A (en) 1984-08-16 1986-07-29 G. D. Searle & Co. Kojic acid ether-ester derivatives
US4812474A (en) * 1984-08-16 1989-03-14 G. D. Searle & Co. Kojic acid ether-ester derivatives
US4735964A (en) * 1984-08-16 1988-04-05 G. D. Searle & Co. Kojic acid ether-ester derivatives
CA1317298C (en) * 1987-03-03 1993-05-04 Upjohn Company (The) Antibiotic sulfonylaminocarbonyl activated .beta.-lactams
GB2280435A (en) 1993-07-29 1995-02-01 Merck & Co Inc Anti-viral agent
ES2244967T3 (es) * 1995-09-29 2005-12-16 Novartis Ag Nuevas hidroxipiridinonas.
GB9711093D0 (en) 1997-05-29 1997-07-23 British Tech Group Novel orally active iron (III) chelators
US6452008B2 (en) * 1998-02-25 2002-09-17 Sumitomo Pharmaceuticals Company, Limited Pyridone derivatives and process for preparing the same
US7256286B2 (en) * 1999-11-30 2007-08-14 The Board Of Trustees Of The Leland Stanford Junior University Bryostatin analogues, synthetic methods and uses
US6939883B2 (en) * 2001-08-02 2005-09-06 Neurocrine Biosciences, Inc. Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
US6426418B1 (en) * 2001-11-02 2002-07-30 Apotex, Inc. Processes for the manufacturing of 3-hydroxy-N,1,6-trialkyl-4-oxo-1,4-dihydropyridine-2-carboxamide
CA2379370A1 (en) 2002-03-28 2003-09-28 Apotex Inc. Carboxylic acid derivatives of 3-hydroxy-4-oxo-1,4-dihydropyridine as iron chelators
CA2498111A1 (en) 2002-09-11 2004-03-25 Merck & Co., Inc. Dihydroxypyridopyrazine-1,6-dione compounds useful as hiv integrase inhibitors
WO2004035577A2 (en) * 2002-10-16 2004-04-29 Gilead Sciences, Inc. Pre-organized tricyclic integrase inhibitor compounds
TW200510425A (en) * 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
DE10349500A1 (de) 2003-10-23 2005-06-02 Bayer Cropscience Ag Verfahren zum Herstellen von 2-Dihalogenacyl-3-amino-acrylsäureestern und 3-Dihalogenmethyl-pyrazol-4-carbonsäureestern
JP4847677B2 (ja) * 2003-10-28 2011-12-28 富士通株式会社 化合物半導体装置の製造方法
JP2005134333A (ja) * 2003-10-31 2005-05-26 Espec Corp 気体流量測定装置、及び気体流量測定方法
NZ529657A (en) * 2003-11-20 2004-07-30 Apotex Inc Iron chelating cycloalkyl derivatives of 3-hydroxy-4-pyridinones
US20070161639A1 (en) 2004-03-09 2007-07-12 Philip Jones Hiv integrase inhibitors
US7820680B2 (en) 2004-03-09 2010-10-26 Merck & Co., Inc. HIV integrase inhibitors
WO2005117904A2 (en) * 2004-04-14 2005-12-15 Gilead Sciences, Inc. Phosphonate analogs of hiv integrase inhibitor compounds
WO2005110399A2 (en) * 2004-04-29 2005-11-24 The Regents Of The University Of California Zinc-binding groups for metalloprotein inhibitors
US6994683B1 (en) * 2004-08-04 2006-02-07 David Starr Portable lumbar traction device
JP4953297B2 (ja) * 2004-09-15 2012-06-13 塩野義製薬株式会社 Ｈｉｖインテグラーゼ阻害活性を有するカルバモイルピリドン誘導体
US20060066414A1 (en) * 2004-09-28 2006-03-30 Rockwell Scientific Licensing, Llc Method and apparatus for changing the polarization of a signal
US7660428B2 (en) * 2004-10-25 2010-02-09 Polycom, Inc. Ceiling microphone assembly
CA2488034C (en) * 2004-11-19 2009-10-06 Apotex Inc. Process for the manufacture of 3-hydroxy-n-alkyl-1-cycloalkyl-6-alkyl-4-oxo-1,4-dihydropyridine-2-carboxamide and its related analogues
WO2006066414A1 (en) 2004-12-23 2006-06-29 Virochem Pharma Inc. Hydroxydihydropyridopy razine-1,8-diones and methods for inhibiting hiv integrase
ATE516026T1 (de) 2005-02-21 2011-07-15 Shionogi & Co Bicyclisches carbamoylpyridonderivat mit hiv- integrase-hemmender wirkung
US7730384B2 (en) * 2005-02-28 2010-06-01 Agere Systems Inc. Method and apparatus for evaluating performance of a read channel
US20060246196A1 (en) 2005-04-27 2006-11-02 Lawson John A Low-alcohol, low-calorie wine
UA96568C2 (en) * 2005-04-28 2011-11-25 Глаксосмиткляйн Ллк Polycyclic carbamoyl pyridone derivative as hiv-integrase inhibitor
KR101363875B1 (ko) * 2005-04-28 2014-02-21 시오노기세야쿠 가부시키가이샤 Ｈｉｖ 통합효소 억제 활성을 가지는 다환식카르바모일피리돈 유도체
AR057023A1 (es) 2005-05-16 2007-11-14 Gilead Sciences Inc Compuestos heterociclicos con propiedades inhibidoras de hiv-integrasa
JP2006342115A (ja) 2005-06-10 2006-12-21 Shionogi & Co Ltd Ｈｉｖインテグラーゼ阻害活性を有する多環性化合物
US20100098640A1 (en) * 2005-06-20 2010-04-22 Cohen Seth M Multidentate Pyrone-Derived Chelators for Medicinal Imaging and Chelation
JP2007056107A (ja) * 2005-08-23 2007-03-08 Sumitomo Rubber Ind Ltd タイヤ用ゴム組成物およびそれからなる補強層を有するランフラットタイヤ
EP1762250A1 (en) * 2005-09-12 2007-03-14 Fresenius Kabi Deutschland GmbH Conjugates of hydroxyalkyl starch and an active substance, prepared by chemical ligation via thiazolidine
MX2008005137A (es) * 2005-10-27 2008-09-29 Shionogi & Co Derivado de carbamoilpiridona policiclica que tiene actividad inhibidora en vih integrasa.
GB0623768D0 (en) * 2006-11-28 2007-01-10 Chopra Sunil A bleomycin preparation for use against skin tumours
WO2008071387A1 (en) 2006-12-11 2008-06-19 Topotarget A/S Prodrugs of diphenyl ox- indol- 2 -one compounds for the treatment of cancers
JP5074042B2 (ja) * 2007-01-10 2012-11-14 Ｈｏｙａ株式会社 情報記録媒体基板用素材、情報記録媒体基板、情報記録媒体それぞれの製造方法
MX2009008531A (es) 2007-02-16 2009-08-26 Amgen Inc Cetonas de heterociclilo que contienen nitrogeno y su uso como inhibidores de c-met.
ES2448766T3 (es) * 2008-07-25 2014-03-17 Viiv Healthcare Company Profármacos de dolutegravir
JP5551697B2 (ja) * 2008-07-25 2014-07-16 ビーブ・ヘルスケア・カンパニー 化合物
WO2010011814A1 (en) 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
US8309008B2 (en) * 2008-10-30 2012-11-13 Molecular Imprints, Inc. Separation in an imprint lithography process
KR101733625B1 (ko) * 2008-12-11 2017-05-10 시오노기세야쿠 가부시키가이샤 카르바모일피리돈 ｈｉｖ 인테그라제 억제제 및 중간체의 합성
CN102245572B (zh) * 2008-12-11 2015-03-25 盐野义制药株式会社 氨甲酰基吡啶酮hiv整合酶抑制剂的方法和中间体
TWI518084B (zh) * 2009-03-26 2016-01-21 鹽野義製藥股份有限公司 哌喃酮與吡啶酮衍生物之製造方法
TWI582097B (zh) 2010-03-23 2017-05-11 Ｖｉｉｖ醫療保健公司 製備胺甲醯吡啶酮衍生物及中間體之方法
ES2608377T3 (es) 2010-08-05 2017-04-10 Shionogi & Co., Ltd. Procedimiento de preparación de un compuesto que tiene actividad inhibidora de la integrasa del HIV

Also Published As

Publication number Publication date
KR101700267B1 (ko) 2017-01-26
JP2014193898A (ja) 2014-10-09
EP2320909A4 (en) 2012-01-04
KR101772610B1 (ko) 2017-09-12
US9133216B2 (en) 2015-09-15
CN103951643B (zh) 2015-12-09
EP2320909A1 (en) 2011-05-18
US8580967B2 (en) 2013-11-12
KR101695807B1 (ko) 2017-01-13
US8981129B2 (en) 2015-03-17
ES2562452T3 (es) 2016-03-04
US8940912B2 (en) 2015-01-27
US20140031555A1 (en) 2014-01-30
US20150335667A1 (en) 2015-11-26
KR20160141867A (ko) 2016-12-09
US20140256961A1 (en) 2014-09-11
EP2320909B8 (en) 2016-03-30
KR20110051207A (ko) 2011-05-17
EP2660239B1 (en) 2016-11-23
US20110183940A1 (en) 2011-07-28
CN103951643A (zh) 2014-07-30
CN102149385A (zh) 2011-08-10
PT2660239T (pt) 2017-02-24
JP2011529070A (ja) 2011-12-01
US9012650B2 (en) 2015-04-21
US9707246B2 (en) 2017-07-18
ES2607403T3 (es) 2017-03-31
CN105198804B (zh) 2018-03-23
CN102149385B (zh) 2015-04-01
JP5586602B2 (ja) 2014-09-10
EP2320909B1 (en) 2016-01-06
KR20160141868A (ko) 2016-12-09
US20140256679A1 (en) 2014-09-11
WO2010011814A1 (en) 2010-01-28
CN105198804A (zh) 2015-12-30
EP2660239A1 (en) 2013-11-06
JP5738457B2 (ja) 2015-06-24
US20150183803A1 (en) 2015-07-02
US8765965B2 (en) 2014-07-01
US20140039207A1 (en) 2014-02-06

Similar Documents

Publication Publication Date Title
US9707246B2 (en) Substituted (3S,11AR)-N-[(2,4-difluorophenyl)methyl]-6-oxy-3-methyl-5,7-dioxo-2,3,5,7,11,11A-hexahydro[1,3]oxazolo[3,2-A]pyrido[1,2-D]pyrazine-8-carboxamides as HIV agents
US8217034B2 (en) Chemical compounds
US8183372B2 (en) Substituted 9,11-dioxo-2,3,4a,5,9,11,13,13a-octahydor-1H-pyrido[1,2-a]pyrrolo[1′,2′:3,4]imidazo[1,2-d]pyrazines
WO2010011815A1 (en) Chemical compounds
WO2010011819A1 (en) Chemical compounds
WO2010011818A1 (en) Chemical compounds
HK1190711A (en) Chemical compounds as synthetic intermediates